Herpesin (Aciclovir)

Herpesin (aciclovir) is indicated for the treatment and management of several herpes virus infections, primarily when systemic therapy is required.

• Primary genital herpes (herpes simplex virus type 2) outbreaks.
• Recurrent oral herpes (herpes labialis) episodes.
• Initial or recurrent herpes zoster (shingles) in immunocompetent adults.
• Suppressive therapy to reduce the frequency of recurrent herpes simplex episodes.
• Post‑exposure prophylaxis for susceptible individuals after known exposure to HSV.
• Herpes simplex encephalitis in selected cases.
• Herpes simplex infections in immunocompromised patients when oral therapy is appropriate.

• Aciclovir is a nucleoside analogue that, after entering infected cells, is phosphorylated by viral thymidine kinase to aciclovir monophosphate and subsequently to the active triphosphate form by cellular kinases. The triphosphate competitively inhibits viral DNA polymerase and incorporates into viral DNA, causing premature chain termination and preventing replication of herpes simplex virus and varicella‑zoster virus. Because the initial phosphorylation step relies on viral enzymes, the drug preferentially accumulates in infected cells, enhancing its selectivity.

Adverse reactions to Herpesin are generally mild, but serious events can occur, especially in susceptible individuals. These reactions are reported in clinical studies and post‑marketing surveillance. Most patients experience only mild symptoms that resolve after discontinuation, while serious events require immediate medical attention.

Common

• Nausea or vomiting.
• Diarrhea.
• Headache.
• Dizziness or vertigo.
• Transient elevation of liver enzymes.
• Mild abdominal discomfort.
• Fatigue.

Serious

• Acute renal failure, especially when dehydration is present.
• Severe allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome.
• Hematologic abnormalities including neutropenia or thrombocytopenia.
• Seizures in patients with pre‑existing renal impairment.
• Hepatic dysfunction, indicated by marked transaminase elevation.
• Cardiac arrhythmias, particularly in patients with electrolyte disturbances.

When prescribing Herpesin, clinicians should evaluate patient history and monitor for conditions that may increase the risk of adverse outcomes.

• Assess renal function before initiating therapy; dose adjustment may be needed in impairment.
• Use caution in patients with a history of hypersensitivity to aciclovir or related compounds.
• Monitor liver enzymes during prolonged treatment, especially in patients with hepatic disease.
• Avoid use in the first trimester of pregnancy unless benefits outweigh risks; category B1 indicates limited data.
• Counsel patients to maintain adequate hydration to reduce renal toxicity.
• Consider alternative antiviral agents for immunocompromised individuals with severe infections.

Herpesin may interact with other medicines that affect renal clearance, hematologic function, or immune response, potentially altering its effectiveness or safety profile.

Avoid

• Concomitant use with nephrotoxic agents such as aminoglycosides or non‑steroidal anti‑inflammatory drugs (NSAIDs) that may increase the risk of renal impairment.
• Co‑administration with myelosuppressive chemotherapy agents, which can exacerbate hematologic toxicity.
• Combining with other antiviral nucleoside analogues (e.g., ganciclovir) without dose adjustment, due to additive toxicity.

Use with caution

• Adjust dose when given with probenecid, which reduces aciclovir renal excretion.
• Monitor for increased plasma levels when used alongside drugs that compete for tubular secretion, such as cimetidine.
• Use carefully in patients receiving immunosuppressants, as infection severity may be altered.